Sonia Jaramillo
Heidelberg, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Late-onset NPM1 mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib.
Journal: Haematologica
Published: January 10, 2024
Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question.
Journal: Haematologica
Published: February 01, 2023
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Journal: Trials
Published: November 26, 2021
Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
Journal: Current oncology reports
Published: May 20, 2021
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML.
Journal: Trials
Published: April 27, 2021
Validation of a proxy-reported SARC-F questionnaire for current and retrospective screening of sarcopenia-related functional impairments.
Journal: Journal of cachexia, sarcopenia and muscle
Published: January 25, 2021
Ruxolitinib is effective in the treatment of a patient with refractory T-ALL.
Journal: EJHaem
Published: October 27, 2020
Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).
Journal: Haematologica
Published: December 26, 2019
Last Updated: 09/26/2026